Scholarlink

<p>Acquired aplastic anemia (AA) is a rare blood disorder causing hypocellular bone marrow due to immune damage to hematopoietic stem cells, leading to low blood cell counts. This study investigates the demographics, treatment patterns, and clinical outcomes of AA in Turkiye. In this non-interventional, retrospective descriptive study, data of 274 patients (Female/Male: 4/5) diagnosed with AA between September 1, 2011, and September 1, 2021, were collected from 16 centers. Severe and very severe AA was diagnosed in 72% and 27.7% of patients, respectively. The mean time from diagnosis to first treatment was 119 ± 287 days, while time to hematopoietic stem cell transplantation (HSCT) was 212 ± 321 days, and to Anti-Thymocyte Globulin (ATG) was 87 ± 242.5 days. The mean time to response after first-line and second-line treatment was 172.9 ± 264.6 days and 191.9 ± 211.9 days, respectively. The mean overall survival of patients with AA was 3.56 ± 3.12 years, with a 5-year overall survival rate of 72.6%. HSCT and other initial treatments led to full or partial remission for most patients, improving survival rates for over half of them. The study observed comparable patterns to previous studies, providing vital insights into Turkiye’s acquired AA treatment landscape.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Assessment of characteristics and treatment patterns of adult patients with acquired aplastic anemia in Turkiye (PLANE-TR)

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月20日

查看全文
  • Eren Gunduz,
  • Turgay Ulas,
  • Fahir Ozkalemkas,
  • Selami Kocak Toprak,
  • Elifcan Aladag Karakulak,
  • Muhlis Cem Ar,
  • Zafer Gulbas,
  • Vildan Ozkocaman,
  • Merve Aydogan,
  • Yahya Buyukasik,
  • Melis Dila Ozer Cerme,
  • Ozgur Mehtap,
  • Damlanur Kucur,
  • Emin Kaya,
  • Irfan Yavasoglu,
  • Sevgi Kalayoglu Besisik,
  • Tuba Ersal,
  • Merve Yuksel,
  • Sibel Hacioglu,
  • Tuba Hacibekiroglu,
  • Ahmet Kaya,
  • Elif Sakci,
  • Meltem Kurt Yuksel,
  • Gulsum Ozet,
  • Gulsum Akgun Cagliyan,
  • Ulviyya Hasanzade,
  • Ozan Salim,
  • Mehmet Sezgin Pepeler,
  • Mehmet Turgut,
  • Derya Deniz Kurekci,
  • Asli Odabasi Giden,
  • Seray Sener,
  • Sinem Calika,
  • Mehmet Sinan Dal

摘要

Acquired aplastic anemia (AA) is a rare blood disorder causing hypocellular bone marrow due to immune damage to hematopoietic stem cells, leading to low blood cell counts. This study investigates the demographics, treatment patterns, and clinical outcomes of AA in Turkiye. In this non-interventional, retrospective descriptive study, data of 274 patients (Female/Male: 4/5) diagnosed with AA between September 1, 2011, and September 1, 2021, were collected from 16 centers. Severe and very severe AA was diagnosed in 72% and 27.7% of patients, respectively. The mean time from diagnosis to first treatment was 119 ± 287 days, while time to hematopoietic stem cell transplantation (HSCT) was 212 ± 321 days, and to Anti-Thymocyte Globulin (ATG) was 87 ± 242.5 days. The mean time to response after first-line and second-line treatment was 172.9 ± 264.6 days and 191.9 ± 211.9 days, respectively. The mean overall survival of patients with AA was 3.56 ± 3.12 years, with a 5-year overall survival rate of 72.6%. HSCT and other initial treatments led to full or partial remission for most patients, improving survival rates for over half of them. The study observed comparable patterns to previous studies, providing vital insights into Turkiye’s acquired AA treatment landscape.